CN101410120A - 抗炎的膦酸酯化合物 - Google Patents
抗炎的膦酸酯化合物 Download PDFInfo
- Publication number
- CN101410120A CN101410120A CN2004800145255A CN200480014525A CN101410120A CN 101410120 A CN101410120 A CN 101410120A CN 2004800145255 A CN2004800145255 A CN 2004800145255A CN 200480014525 A CN200480014525 A CN 200480014525A CN 101410120 A CN101410120 A CN 101410120A
- Authority
- CN
- China
- Prior art keywords
- conjugate
- general formula
- chemical compound
- following general
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
- C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (152)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60/465,420 | 2003-04-25 | ||
| US60/465,560 | 2003-04-25 | ||
| US60/465,695 | 2003-04-25 | ||
| US60/465,844 | 2003-04-25 | ||
| US60/465,479 | 2003-04-25 | ||
| US60/465532 | 2003-04-25 | ||
| US60/465,746 | 2003-04-25 | ||
| US60/465,433 | 2003-04-25 | ||
| US60/465,749 | 2003-04-25 | ||
| US60/465,377 | 2003-04-25 | ||
| US60/465,332 | 2003-04-25 | ||
| US60/465,452 | 2003-04-25 | ||
| US60/465,632 | 2003-04-25 | ||
| US60/465,419 | 2003-04-25 | ||
| US60/465,449 | 2003-04-25 | ||
| US60/465,335 | 2003-04-25 | ||
| US60/465,480 | 2003-04-25 | ||
| US60/465,620 | 2003-04-25 | ||
| US60/465,638 | 2003-04-25 | ||
| US60/465,682 | 2003-04-25 | ||
| US60/465,683 | 2003-04-25 | ||
| US60/465,406 | 2003-04-25 | ||
| US60/465,547 | 2003-04-25 | ||
| US60/465,531 | 2003-04-25 | ||
| US60/465,756 | 2003-04-25 | ||
| US60/465,424 | 2003-04-25 | ||
| US60/465,481 | 2003-04-25 | ||
| US60/465,373 | 2003-04-25 | ||
| US60/465,342 | 2003-04-25 | ||
| US60/465,658 | 2003-04-25 | ||
| US60/465,380 | 2003-04-25 | ||
| US60/465,640 | 2003-04-25 | ||
| US60/465,422 | 2003-04-25 | ||
| US60/465581 | 2003-04-25 | ||
| US60/493303 | 2003-08-07 | ||
| US60/493,302 | 2003-08-07 | ||
| US60/493309 | 2003-08-07 | ||
| US60/493,310 | 2003-08-07 | ||
| US60/495661 | 2003-08-15 | ||
| US60/495,533 | 2003-08-15 | ||
| US60/495,366 | 2003-08-15 | ||
| US60/495,754 | 2003-08-15 | ||
| US60/495,295 | 2003-08-15 | ||
| US60/495,537 | 2003-08-15 | ||
| US60/495,425 | 2003-08-15 | ||
| US60/495,680 | 2003-08-15 | ||
| US60/495,471 | 2003-08-15 | ||
| US60/495,456 | 2003-08-15 | ||
| US60/495,276 | 2003-08-15 | ||
| US60/495,393 | 2003-08-15 | ||
| US60/495,414 | 2003-08-15 | ||
| US60/495,380 | 2003-08-15 | ||
| US60/495,472 | 2003-08-15 | ||
| US60/495,398 | 2003-08-15 | ||
| US60/495,752 | 2003-08-15 | ||
| US60/495,532 | 2003-08-15 | ||
| US60/495,597 | 2003-08-15 | ||
| US60/495,679 | 2003-08-15 | ||
| US60/495,460 | 2003-08-15 | ||
| US60/495,748 | 2003-08-15 | ||
| US60/495,529 | 2003-08-15 | ||
| US60/495,389 | 2003-08-15 | ||
| US60/495,416 | 2003-08-15 | ||
| US60/495,660 | 2003-08-15 | ||
| US60/495,563 | 2003-08-15 | ||
| US60/495427 | 2003-08-15 | ||
| US60/495,375 | 2003-08-15 | ||
| US60/495,274 | 2003-08-15 | ||
| US60/495,614 | 2003-08-15 | ||
| US60/495,691 | 2003-08-15 | ||
| US60/495,530 | 2003-08-15 | ||
| US60/495,455 | 2003-08-15 | ||
| US60/495,749 | 2003-08-15 | ||
| US51425803P | 2003-10-24 | 2003-10-24 | |
| US60/514,280 | 2003-10-24 | ||
| US60/514,203 | 2003-10-24 | ||
| US60/513,530 | 2003-10-24 | ||
| US60/514,174 | 2003-10-24 | ||
| US60/514,450 | 2003-10-24 | ||
| US60/514,258 | 2003-10-24 | ||
| US60/514,131 | 2003-10-24 | ||
| US60/514,097 | 2003-10-24 | ||
| US60/514,051 | 2003-10-24 | ||
| US60/514,325 | 2003-10-24 | ||
| US60/513,951 | 2003-10-24 | ||
| US60/514,044 | 2003-10-24 | ||
| US60/513,924 | 2003-10-24 | ||
| US60/514,130 | 2003-10-24 | ||
| US60/514,175 | 2003-10-24 | ||
| US60/514,143 | 2003-10-24 | ||
| US60/514,326 | 2003-10-24 | ||
| US60/514,394 | 2003-10-24 | ||
| US60/514,205 | 2003-10-24 | ||
| US60/514,206 | 2003-10-24 | ||
| US60/513,531 | 2003-10-24 | ||
| US60/513,561 | 2003-10-24 | ||
| US60/513,953 | 2003-10-24 | ||
| US60/513,950 | 2003-10-24 | ||
| US60/513,945 | 2003-10-24 | ||
| US60/514,161 | 2003-10-24 | ||
| US60/513,592 | 2003-10-24 | ||
| US60/513,947 | 2003-10-24 | ||
| US60/514,075 | 2003-10-24 | ||
| US60/514140 | 2003-10-24 | ||
| US60/514,424 | 2003-10-24 | ||
| US60/514,072 | 2003-10-24 | ||
| US60/514,334 | 2003-10-24 | ||
| US60/513,970 | 2003-10-24 | ||
| US60/514,021 | 2003-10-24 | ||
| US60/513,975 | 2003-10-24 | ||
| US60/514,200 | 2003-10-24 | ||
| US60/514,204 | 2003-10-24 | ||
| US60/513,982 | 2003-10-24 | ||
| US60/513,563 | 2003-10-24 | ||
| US60/513,944 | 2003-10-24 | ||
| US60/513,588 | 2003-10-24 | ||
| US60/514,113 | 2003-10-24 | ||
| US60/514,466 | 2003-10-24 | ||
| US60/514,160 | 2003-10-24 | ||
| US60/514,144 | 2003-10-24 | ||
| US60/513,961 | 2003-10-24 | ||
| US60/514,244 | 2003-10-24 | ||
| US60/514,098 | 2003-10-24 | ||
| US60/514,324 | 2003-10-24 | ||
| US60/514,107 | 2003-10-24 | ||
| US60/514,360 | 2003-10-24 | ||
| US60/514,111 | 2003-10-24 | ||
| US60/514,110 | 2003-10-24 | ||
| US60/514,298 | 2003-10-24 | ||
| US60/513,946 | 2003-10-24 | ||
| US60/513,979 | 2003-10-24 | ||
| US60/513,971 | 2003-10-24 | ||
| US60/514,522 | 2003-10-24 | ||
| US60/514,201 | 2003-10-24 | ||
| US60/514,393 | 2003-10-24 | ||
| US60/513,579 | 2003-10-24 | ||
| US60/513,976 | 2003-10-24 | ||
| US60/514,054 | 2003-10-24 | ||
| US60/514,085 | 2003-10-24 | ||
| US60/514,116 | 2003-10-24 | ||
| US60/514,202 | 2003-10-24 | ||
| US60/513593 | 2003-10-24 | ||
| US60/513948 | 2003-10-24 | ||
| US60/513,589 | 2003-10-24 | ||
| US60/513,977 | 2003-10-24 | ||
| US60/513,973 | 2003-10-24 | ||
| US60/514464 | 2003-10-24 | ||
| US60/513,562 | 2003-10-24 | ||
| US60/514,453 | 2003-10-24 | ||
| US60/532,160 | 2003-12-22 | ||
| US60/531,940 | 2003-12-22 | ||
| PCT/US2004/013198 WO2004100960A2 (en) | 2003-04-25 | 2004-04-26 | Anti-inflammatory phosphonate compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101410120A true CN101410120A (zh) | 2009-04-15 |
Family
ID=38344791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2004800145255A Pending CN101410120A (zh) | 2003-04-25 | 2004-04-26 | 抗炎的膦酸酯化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070027116A1 (https=) |
| EP (1) | EP1680129A2 (https=) |
| JP (1) | JP2007520452A (https=) |
| CN (1) | CN101410120A (https=) |
| AU (1) | AU2004283710A1 (https=) |
| CA (1) | CA2542967A1 (https=) |
| WO (1) | WO2005039552A2 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106565769A (zh) * | 2016-11-12 | 2017-04-19 | 青岛云天生物技术有限公司 | 恩替卡韦中间体的合成工艺 |
| CN110726801A (zh) * | 2019-10-31 | 2020-01-24 | 山东泰星新材料股份有限公司 | 一种监测烷基次膦酸反应状态的方法 |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA014685B1 (ru) | 2003-04-25 | 2010-12-30 | Джилид Сайэнс, Инк. | Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе |
| MXPA06005659A (es) | 2004-04-26 | 2007-04-10 | Teva Gyogyszergyar Zartkoruen | Proceso para preparacion de acido micofenolico y derivados de ester del mismo. |
| AU2005330489B2 (en) | 2004-07-27 | 2011-08-25 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates as anti HIV agents |
| EP1906971A2 (en) * | 2005-07-27 | 2008-04-09 | Gilead Sciences, Inc. | Antiviral compounds |
| DE102005057924A1 (de) * | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| US8658617B2 (en) | 2008-07-08 | 2014-02-25 | Gilead Sciences, Inc. | Salts of HIV inhibitor compounds |
| CN102282155B (zh) | 2008-12-02 | 2017-06-09 | 日本波涛生命科学公司 | 磷原子修饰的核酸的合成方法 |
| JP2012521359A (ja) * | 2009-03-20 | 2012-09-13 | アリオス バイオファーマ インク. | 置換されたヌクレオシドアナログおよびヌクレオチドアナログ |
| US8530492B2 (en) * | 2009-04-17 | 2013-09-10 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
| WO2010120388A1 (en) | 2009-04-17 | 2010-10-21 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
| RU2612521C2 (ru) | 2009-07-06 | 2017-03-09 | Онтории, Инк. | Новые пролекарства нуклеиновых кислот и способы их применения |
| NZ607996A (en) | 2010-09-22 | 2014-07-25 | Alios Biopharma Inc | Substituted nucleotide analogs |
| JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
| CN103796657B (zh) | 2011-07-19 | 2017-07-11 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
| HK1206362A1 (zh) | 2012-03-21 | 2016-01-08 | Alios Biopharma, Inc. | 硫代氨基磷酸酯核苷酸前藥的固體形式 |
| WO2013142157A1 (en) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| PL2872485T3 (pl) | 2012-07-13 | 2021-05-31 | Wave Life Sciences Ltd. | Asymetryczna grupa pomocnicza |
| BR112016016400A2 (pt) | 2014-01-16 | 2017-10-03 | Wave Life Sciences Ltd | Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | N4-ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| SI3661937T1 (sl) | 2017-08-01 | 2021-11-30 | Gilead Sciences, Inc. | Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb |
| PT3706762T (pt) | 2017-12-07 | 2024-12-05 | Univ Emory | N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos |
| IT202100005777A1 (it) | 2021-03-11 | 2022-09-11 | Hippocrates Res S R L | Composizione per l’uso nel trattamento dell’occhio secco |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5631370A (en) * | 1988-01-20 | 1997-05-20 | Regents Of The University Of Minnesota | Optically-active isomers of dideoxycarbocyclic nucleosides |
| US5177064A (en) * | 1990-07-13 | 1993-01-05 | University Of Florida | Targeted drug delivery via phosphonate derivatives |
| US5610294A (en) * | 1991-10-11 | 1997-03-11 | The Du Pont Merck Pharmaceutical Company | Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors |
| IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| US5654286A (en) * | 1993-05-12 | 1997-08-05 | Hostetler; Karl Y. | Nucleotides for topical treatment of psoriasis, and methods for using same |
| EP0708760A1 (en) * | 1993-07-14 | 1996-05-01 | Novartis AG | Cyclic hydrazine compounds |
| US5446137B1 (en) * | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
| US5493030A (en) * | 1994-02-18 | 1996-02-20 | Syntex (U.S.A.) Inc. | 5-substituted derivatives of mycophenolic acid |
| US5854227A (en) * | 1994-03-04 | 1998-12-29 | Hartmann; John F. | Therapeutic derivatives of diphosphonates |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5750493A (en) * | 1995-08-30 | 1998-05-12 | Raymond F. Schinazi | Method to improve the biological and antiviral activity of protease inhibitors |
| US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5874577A (en) * | 1996-04-03 | 1999-02-23 | Medichem Research, Inc. | Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof |
| CA2261619C (en) * | 1996-07-26 | 2006-05-23 | Gilead Sciences, Inc. | Nucleotide analogs |
| US6312662B1 (en) * | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| US6174888B1 (en) * | 1998-05-28 | 2001-01-16 | Novartis Ag | 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydropyrrolo[3,2-D]pyrimidin-4-ones |
| TNSN00027A1 (fr) * | 1999-02-12 | 2005-11-10 | Vertex Pharma | Inhibiteurs de l'aspartyle protease |
| US6258831B1 (en) * | 1999-03-31 | 2001-07-10 | The Procter & Gamble Company | Viral treatment |
| US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| ATE248835T1 (de) * | 1999-06-25 | 2003-09-15 | Vertex Pharma | Prodrugs von impdh-inhibierenden carbamaten |
| CN1426418A (zh) * | 2000-02-29 | 2003-06-25 | 三菱制药株式会社 | 膦酸酯核苷酸化合物 |
| US20020119443A1 (en) * | 2000-07-21 | 2002-08-29 | Gilead Sciences, Inc. | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| KR20020097384A (ko) * | 2001-06-20 | 2002-12-31 | 미쯔비시 도꾜 세이야꾸 가부시끼가이샤 | 기존의 약제에 내성변이를 가지는 바이러스에 유효한 약제 |
| WO2003091264A2 (en) * | 2002-04-26 | 2003-11-06 | Gilead Sciences, Inc. | Non nucleoside reverse transcriptase inhibitors |
| CN102174038A (zh) * | 2003-02-19 | 2011-09-07 | 耶鲁大学 | 用于治疗病毒感染的抗病毒核苷 |
-
2004
- 2004-04-26 CN CN2004800145255A patent/CN101410120A/zh active Pending
- 2004-10-25 EP EP04817344A patent/EP1680129A2/en not_active Withdrawn
- 2004-10-25 WO PCT/US2004/035136 patent/WO2005039552A2/en not_active Ceased
- 2004-10-25 CA CA002542967A patent/CA2542967A1/en not_active Abandoned
- 2004-10-25 AU AU2004283710A patent/AU2004283710A1/en not_active Abandoned
- 2004-10-25 JP JP2006536844A patent/JP2007520452A/ja not_active Withdrawn
-
2006
- 2006-04-19 US US11/406,750 patent/US20070027116A1/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106565769A (zh) * | 2016-11-12 | 2017-04-19 | 青岛云天生物技术有限公司 | 恩替卡韦中间体的合成工艺 |
| CN106565769B (zh) * | 2016-11-12 | 2018-12-04 | 北京汇康博源医药科技有限公司 | 恩替卡韦中间体的合成工艺 |
| CN110726801A (zh) * | 2019-10-31 | 2020-01-24 | 山东泰星新材料股份有限公司 | 一种监测烷基次膦酸反应状态的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004283710A1 (en) | 2005-05-06 |
| EP1680129A2 (en) | 2006-07-19 |
| WO2005039552A2 (en) | 2005-05-06 |
| CA2542967A1 (en) | 2005-05-06 |
| US20070027116A1 (en) | 2007-02-01 |
| WO2005039552A3 (en) | 2005-06-09 |
| JP2007520452A (ja) | 2007-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101914124B (zh) | 作为抗hiv剂的核苷膦酸酯缀合物 | |
| US7470724B2 (en) | Phosphonate compounds having immuno-modulatory activity | |
| JP5069463B2 (ja) | 抗ウイルス性ホスホネート類似物 | |
| CN101410120A (zh) | 抗炎的膦酸酯化合物 | |
| US7300924B2 (en) | Anti-infective phosphonate analogs | |
| WO2005002626A2 (en) | Therapeutic phosphonate compounds | |
| KR20040108756A (ko) | 비뉴클레오사이드 역전사 효소 억제제 | |
| JP2009501724A (ja) | 抗ウイルス性化合物 | |
| US20090247488A1 (en) | Anti-inflammatory phosphonate compounds | |
| JP2007254479A (ja) | 免疫調節性ホスホネート抱合体 | |
| US7427636B2 (en) | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds | |
| US7432261B2 (en) | Anti-inflammatory phosphonate compounds | |
| KR20060028632A (ko) | 항염증 포스포네이트 화합물 | |
| CN1780643B (zh) | 抗病毒的膦酸酯类似物 | |
| JP2007246533A (ja) | 抗炎症性ホスホネート化合物 | |
| JP2007536194A (ja) | 免疫調節性ホスホネート抱合体 | |
| CN101027312A (zh) | 抗病毒化合物 | |
| KR20060061292A (ko) | 면역 억제 작용을 갖는 포스포네이트 화합물 | |
| JP2008518015A (ja) | ホスホネート置換キナーゼ阻害剤 | |
| CA2523045A1 (en) | Anti-inflammatory phosphonate compounds | |
| CN1780630A (zh) | 具有免疫调节活性的膦酸酯化合物 | |
| AU2004238225A1 (en) | Anti-inflammatory phosphonate compounds | |
| AU2004233992A1 (en) | Immunomodulator phosphonate conjugates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090415 |